Veridex, LLC Release: Next-Generation Circulating Tumor Cell Test Demonstrates High Efficiency and Accuracy in New Study
4/4/2013 9:19:38 AM
More...
|
Veridex, LLC and LabCorp Agreement Brings CELLSEARCH® CTC Test to China
1/17/2013 10:05:03 AM
More...
|
Veridex, LLC Release: New Category I CPT Codes and Payment Rates for Circulating Tumor Cell Testing Effective January 1
12/27/2012 10:01:26 AM
More...
|
Veridex, LLC, a Johnson & Johnson (JNJ) Company, Gains OK for Cancer IVD Test in China
12/14/2012 11:21:39 AM
More...
|
Veridex, LLC Release: CellSearch® "Liquid Biopsy" Approved for Breast Cancer Patients in China
12/13/2012 9:26:13 AM
More...
|
Veridex, LLC Release: Updated Coding and Payment on the Horizon for Circulating Tumor Cell Testing
8/10/2012 10:25:56 AM
More...
|
New Veridex, LLC Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
4/24/2012 9:28:51 AM
More...
|
Veridex, LLC Release: Late-Breaking American Society of Clinical Oncology Data Demonstrate Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials
6/6/2011 11:42:45 AM
More...
|
Veridex, LLC Launches CELLTRACKS(R) Circulating Melanoma Cell Kit for Research Use
5/25/2011 8:18:51 AM
More...
|
Veridex, LLC Announces Collaboration to Develop Next-Generation Circulating Tumor Cell (CTC) Technology with Massachusetts General Hospital
1/3/2011 7:50:18 AM
More...
|
|